US-based biotechnology company Immunophotonics has dosed the first patient in the Phase II/III clinical trial of inCVAX for the treatment of breast cancer.

inCVAX is developed as a therapeutic cancer vaccine to trigger an immune response against the primary tumour and distant metastases.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It detects tumour antigens directly from the individual tumour and activates the T-cells to attack the cancerous cells.

inCVAX is administered through two injections into an accessible tumour to trigger the anti-tumour immune response against the cancer.

The randomised, controlled clinical Phase II/III trial is being pursued on the basis of a previously undertaken investigator-initiated clinical trial in Peru, which demonstrated the efficacy of the cancer vaccine in reducing both treated tumours and distant, untreated metastases.

The current Phase II/III trial will enrol 246 patients and has been designed to test the efficacy of inCVAX in treating late-stage breast cancer patients.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"The clinical investigators are eager to enrol patients and we expect to have preliminary results available sometime in Q2-2017."

Immunophotonics co-founder and president Lu Alleruzzo said: “We were encouraged by the investigator-initiated, first-in-human results and are excited to have initiated this follow-on clinical trial.

“The clinical investigators are eager to enrol patients and we expect to have preliminary results available sometime in Q2-2017.”

The company has stated data suggestive of inCVAX to be used on a broader range of solid tumour indications.

Immunophotonics will make a US Investigational New Drug submission for inCVAX next year while exploring options to use the cancer vaccine for other indications including advanced melanoma.

Image: inCVAX triggers anti-cancer immune response. Photo: courtesy of Immunophotonics / GlobeNewswire.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact